Topical Low Dose Preservative-Free Hydrocortisone Reduces Signs and Symptoms in Patients with Chronic Dry Eye: A Randomized Clinical Trial

Purpose Dry eye disease (DED) is a highly prevalent ocular condition with a significant burden on affected patients. Regardless of the underlying etiology, DED is associated with increased ocular surface inflammation. We investigated the safety and efficacy of a short-term treatment with topical low...

Full description

Saved in:
Bibliographic Details
Published in:Advances in therapy 2020, Vol.37 (1), p.329-341
Main Authors: Kallab, Martin, Szegedi, Stephan, Hommer, Nikolaus, Stegmann, Hannes, Kaya, Semira, Werkmeister, René M., Schmidl, Doreen, Schmetterer, Leopold, Garhöfer, Gerhard
Format: Article
Language:English
Subjects:
Cardiology
Endocrinology
Health technology assessment
Internal Medicine
Medicine
Medicine & Public Health
Oncology
Original Research
Pharmacology/Toxicology
Rheumatology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose Dry eye disease (DED) is a highly prevalent ocular condition with a significant burden on affected patients. Regardless of the underlying etiology, DED is associated with increased ocular surface inflammation. We investigated the safety and efficacy of a short-term treatment with topical low dose hydrocortisone in patients with chronic DED and ocular surface inflammation. Methods A total of 60 patients (mean age 51 ± 14 years) with chronic DED and conjunctival hyperemia greater than grade 2 on the Efron scale were included. Patients were randomized to receive either preservative-free hydrocortisone 0.335% (Softacort, Laboratories Thea, France) for 12 days four times daily followed by 2 days twice daily instillation (intense treatment group) or 8 days three times daily followed by 3 days twice daily treatment (standard treatment group). Ocular redness was assessed at baseline, day 14, and day 28. Measurement of intraocular pressure (IOP) and clinical tests to assess signs and symptoms of DED were performed. Results Conjunctival hyperemia and Ocular Surface Disease Index (OSDI) significantly decreased in both treatment groups ( p  
ISSN:0741-238X
1865-8652
DOI:10.1007/s12325-019-01137-8